---
title: ANS
layout: diseases
author: Corbin Cox
last-updated: 2018-6-24
created: 2018-2-8
toc: true
common: true
---

# ANS Overview

## ANS Anatomy

* ANS is subdivided into sympathetic and parasympathetic neurons
* Sympathetic innervations branch from T1-L2 and the sympathetic ganglia lie along both sides of the spinal cord (but the ganglia are higher and lower then the branches innervating them)
* Parasympathetic innervations branch from the brainstem and sacral spine
* All preganglionic neurons utilize acetylcholine
* Sympathetic presynaptic neurons are short, meeting the ganglia near the spinal cord, and have long post-ganglionic neurons. Post-ganglionic neurons from a single ganglion can innervate multiple neurons, and utilize NE as their neurotransmitter
* Parasympathetic preganglionic neurons are long, meeting the ganglia which rest near their target organ. The postganglionic neurons are short, innervate a single organ, and utilize ACh.

## Unique ANS Innervations

* Sweat Glands
  * Post-ganglionic **sympathetic** neurons secrete ACh to stimulate sweating
* Kidneys
  * Sympathetic innervations of renal vasculature secrete **dopamine** to cause vasodilation
* Adrenal Glands
  * The adrenal glands act as sympathetic ganglion, i.e. preganglionic neurons release ACh onto nicotinic receptors in the gland, leading to epinephrine and norepinephrine release into systemic circulation

## ANS Receptors

| Receptor            | Signaling Pathway |
| ------------------- | ----------------- |
| Nicotinic Receptor  | Na Influx         |
| M<sub>1,3,5</sub>   | G<sub>q</sub>     |
| M<sub>2,4</sub>     | G<sub>I/O</sub>   |
| &alpha;<sub>1</sub> | G<sub>q</sub>     |
| &alpha;<sub>2</sub> | G<sub>i</sub>     |
| &beta;              | G<sub>S</sub>     |

| Physiologic Parameter      | Symp. Receptor                                             | Effect                             | Para. Receptor     | Effect                                     |
| -------------------------- | ---------------------------------------------------------- | ---------------------------------- | ------------------ | ------------------------------------------ |
| Chronotropy                | &beta;<sub>1&gt;2</sub>                                    | Increase                           | M<sub>2</sub>      | Decrease                                   |
| Inotropy                   | &beta;<sub>1&gt;2</sub>                                    | Increase                           | M<sub>2</sub>      | Decrease                                   |
| Arteries (most)            | &alpha;<sub>1</sub>                                        | Constrict                          |                    |                                            |
| Veins                      | &alpha;<sub>1,2</sub>                                      | Constrict                          |                    |                                            |
| Skeletal Muscle Vessels    | &beta;<sub>2</sub>                                         | Dilate                             |                    |                                            |
| Endothelium                |                                                            |                                    | M<sub>3</sub>      | Release EDRF (minimal vascular relaxation) |
| Bronchioles                | &beta;<sub>2</sub>                                         | Dilate                             | M<sub>3&gt;2</sub> | Constrict                                  |
| Bladder Wall               | &beta;<sub>2</sub>                                         | Relax                              | M<sub>3</sub>      | Constrict                                  |
| Ureter                     | &alpha;<sub>1</sub>                                        | Contract                           | M<sub>3</sub>      | Relax                                      |
| Urinary Sphincter          | &alpha;<sub>1</sub>                                        | Contract                           | M<sub>3</sub>      | Relax                                      |
| Uterus                     | &beta;<sub>2</sub><br />&alpha;<sub>1</sub>                | Relax<br />Contract                | M<sub>3</sub>      | Variable                                   |
| Penis/Vas Deferens         | &alpha;<sub>1</sub>                                        | Ejaculation                        | M<sub>3</sub>      | Erection                                   |
| Salivary Glands            | &alpha;<sub>1</sub>                                        | Increase Secretion                 | M<sub>3</sub>      | Increase Secretion                         |
| GI Walls                   | &alpha;<sub>2</sub>, &beta;<sub>2</sub>                    | Relax                              | M<sub>2,3</sub>    | Contraction                                |
| GI Sphincters              | &alpha;<sub>1</sub>                                        | Contract                           | M<sub>2,3</sub>    | Relaxation                                 |
| GI Secretions              | &alpha;<sub>2</sub>                                        | Inhibit Secretion                  | M<sub>2,3</sub>    | Increase Secretion                         |
| Skin Follicle Muscles      | &alpha;<sub>1</sub>                                        | Contraction and Piloerection       |                    |                                            |
| Thermoregulatory Sweating  | M<sub>3</sub>                                              | Increase Secretion                 |                    |                                            |
| Stress (Apocrine) Sweating | &alpha;<sub>1</sub>                                        | Increase Secretion                 |                    |                                            |
| Iris Radial Muscle         | &alpha;<sub>1</sub>                                        | Contract                           |                    |                                            |
| Iris Circular Muscle       |                                                            |                                    | M<sub>3</sub>      | Contract                                   |
| Ciliary Muscle             | &beta;<sub>2</sub>                                         | Minor Relaxation                   | M<sub>3</sub>      | Contract                                   |
| Ciliary Epithelium         | &beta;<sub>2</sub>                                         | Increase Aqueous Humor Secretion   |                    |                                            |
| Liver                      | &alpha;<sub>1</sub>, &beta;<sub>2</sub>                    | Gluconeogenesis and Glycogenolysis |                    |                                            |
| Adipose Tissue             | &alpha;<sub>1</sub>, &beta;<sub>1,2,3 (if it exists)</sub> | Lipolysis                          |                    |                                            |
| Kidney                     | &beta;<sub>1</sub>                                         | Increase Renin Release             |                    |                                            |
| Pancreas                   | &alpha;<sub>2</sub>                                        | Decrease insulin release           |                    |                                            |

# Sympathomimetics

| Drug                                                         | Receptor Specificity                                         | Notes                                                        |
| ------------------------------------------------------------ | ------------------------------------------------------------ | ------------------------------------------------------------ |
| Norepinephrine                                               | &alpha;, &beta;                                              | Inopressor                                                   |
| Epinephrine                                                  | &alpha;, &beta;                                              | Inopressor, anaphylaxis, cardiac arrest, vasoconstrictor     |
| Phenylephrine                                                | &alpha;<sub>1</sub>                                          | Mydriasis w/o cycloplegia, push-dose pressor, decongestant   |
| Naphazoline<br />Tetrahydrozoline<br />Oxymetazoline         | &alpha;<sub>1</sub> partial agonist                          | Nasal and ophthalmic decongestant / vasoconstrictor<br />Tachyphylaxis |
| Methyldopa (prodrug)<br />Clonidine<br />Guanabenz<br />Guanfacine<br />Apraclonidine<br />Tizanidine | &alpha;<sub>2</sub>                                          | HTN, vasomotor menopausal SSx, and many psychiatric uses<br />Inhibit preganglionic innervation of heart, kidney, and vascular &alpha;<sub>1</sub> causing bradycardia, decreased renin release, and inhibition of vasoconstriction<br />Apraclonidine is used primarily for glaucoma<br />Tizanidine is primarily used for muscle spasticity |
| Isoproteronol                                                | &beta;                                                       | Used in Asthma, COPD, and as an inotrope                     |
| Metaproterenol<br />Terbutaline<br />Albuterol<br />Salmeterol<br />Formoterol<br />-erols | &beta;<sub>2</sub>                                           | Bronchodilator<br />Terbutaline can be used as a tocolytic in premature labor |
| Dobutamine                                                   | &beta;                                                       | Dopamine derivative<br />**Inotrope w/ little chronotropic activity** due to enantiomers' competing chronotropic actions |
| Amphetamines                                                 | Inhibition of VMAT leading to reversal of DAT, NET, and SERT | Indirect sympathomimetic<br />Used in ADHD, narcolepsy, obesity, and ephedrine and pseudoephedrine are decongestants<br />**Ephedrine is unique and is a direct adrenergic agonist** |
| Cocaine                                                      | NERT, DAT, and SERT Inhibitor                                |                                                              |
| Phenelzine<br />Selegiline                                   | MAOIs                                                        | NE, Epi, Phenylephrine are sensitive                         |

## SEs

* &alpha;<sub>2</sub> Agonists
  * Dry Mouth
  * Increased aldosterone release
  * Sedation
  * Rebound Tachycardia

# Sympatholytics

## &alpha;-Blockers

| Drug             | Receptor Selectivity                                      | Notes                                               |
| ---------------- | --------------------------------------------------------- | --------------------------------------------------- |
| Phenoxybenzamine | &alpha;<sub>1,2</sub>, Histamine, ACh, 5HT (Irreversible) | Useful in HTN crisis and pheochromocytomas          |
| Phentolamine     | &alpha;<sub>1,2</sub>                                     | IV only, useful in HTN crisis and pheochromocytomas |
| Prazosin         | &alpha;<sub>1</sub>                                       | BPH, HTN<br />t<sub>1/2</sub>: 3hr                  |
| Terazosin        | &alpha;<sub>1</sub>                                       | BPH, HTN<br />t<sub>1/2</sub>: 12hr                 |
| Doxazosin        | &alpha;<sub>1</sub>                                       | BPH, HTN<br />t<sub>1/2</sub>: 20hr                 |

### SEs &alpha;<sub>1</sub> Blockade

* Orthostatic Hypotension
* Inhibition of Ejaculation
* Congestion
* Reflex Tachycardia

## &beta;-Blockers

| Drug                 | Receptor Selectivity                                        | ISA  | Usual Maintenance Dose                                       | Notes                                                        |
| -------------------- | ----------------------------------------------------------- | ---- | ------------------------------------------------------------ | ------------------------------------------------------------ |
| Acebutolol           | &beta;<sub>1</sub>                                          | +    | 200-600mg BID                                                |                                                              |
| Atenolol             | &beta;<sub>1</sub>                                          | 0    | 50-100mg QD                                                  |                                                              |
| Betaxolol            | &beta;<sub>1</sub>                                          | 0    | 10-20mg QD                                                   |                                                              |
| Bisoprolol           | &beta;<sub>1</sub>                                          | 0    | 5-10mg QD                                                    | Approved for CHF                                             |
| Carteolol            | &beta;<sub>1</sub>, &beta;<sub>2</sub>                      | ++   | 2.5-10mg QD                                                  | Partial Agonist                                              |
| Carvedilol           | &beta;<sub>1</sub>, &beta;<sub>2</sub>, &alpha;<sub>1</sub> | 0    | 25-50mg BID                                                  | Approved for CHF                                             |
| Esmolol              | &beta;<sub>1</sub>                                          | 0    | HTN Emergency: 500-1000mcg/kg over 1min<br />50-200mcg/kg/min | IV Only<br />t<sub>1/2</sub>: 9min<br />Incompatible w/ Bicarb<br />Useful for rapid HR and BP control as a drip |
| Labetalol            | &beta;<sub>1</sub>, &beta;<sub>2</sub>, &alpha;<sub>1</sub> | 0    | 200-400mg BID                                                | Enantiomers possess different properties                     |
| Metoprolol  Tartrate | &beta;<sub>1</sub>                                          | 0    | 50-100mg BID                                                 |                                                              |
| Metoprolol Succinate | &beta;<sub>1</sub>                                          | 0    | 100-200mg QD                                                 | Approved for CHF                                             |
| Nebivolol            | &beta;<sub>1</sub>                                          | 0    | 5-40mg QD                                                    | Increases NO production                                      |
| Nadolol              | &beta;<sub>1</sub>, &beta;<sub>2</sub>                      | 0    | 40-80mg QD                                                   | t<sub>1/2</sub>: 20hr                                        |
| Penbutolol           | &beta;<sub>1</sub>, &beta;<sub>2</sub>                      | +    | 20mg QD                                                      |                                                              |
| Pindolol             | &beta;<sub>1</sub>, &beta;<sub>2</sub>                      | +++  | 5-20mg BID                                                   | Partial Agonist                                              |
| Propranolol          | &beta;<sub>1</sub>, &beta;<sub>2</sub>                      | 0    | Variable                                                     | Lipophilic<br />Reduces Renin Release                        |
| Propranolol LA       | &beta;<sub>1</sub>, &beta;<sub>2</sub>                      | 0    | 80-160mg QD                                                  |                                                              |
| Timolol              | &beta;<sub>1</sub>, &beta;<sub>2</sub>                      | 0    | 10-20mg BID                                                  | PO and Ophthalmic (Glaucoma)                                 |

### SEs

* Bronchoconstriction (particularly those with &beta;<sub>2</sub> activity)
* Bradycardia / AV Block
* **Difficulty identifying Hypoglycemia**
* **Withdrawal can cause HTN Crisis**
* Fatigue
* Depression
* Nightmares
* Sexual dysfunction

## Catecholamine Depleters

* Reserpine
  * Blocks VMAT inhibiting vesicular loading
  * Lasts for weeks

# Cholinergics

## Cholinergic Toxidrome

**SLUD**

* Salivation
* Lacrimation
* Urination
* Defecation
* Sweating
* Pupil constriction
* Hallucinations
* Bradycardia

## Direct Cholinergic Agents

* Acetylcholine
* Carbachol
* Methacholine
* Bethanechol (Muscharinic Agonist)
* Muscarine
* Nicotine
* Pilocarpine (Muscharinic Agonist)
* Varenicline (Partial Nicotinic Agonist)

## Cholinesterase Inhibitors

* Reversible
  * Edrophonium
    * Dx of Myasthenia Gravis (SSx will resolve almost immediately)
  * Neostigmine
  * Pyridostigmine
  * Physostigmine
    * Anticholinergic antidote
  * Tacrine
  * Donepezil
  * Rivastigmine
  * Galantamine
  * Memantine
* Irreversible
  * Organophosphates
  * Isoflurophate
  * Echothiophate
  * Sarin
  * Soman
  * Malathion
  * Diazinon

### Treatment of Anticholinesterase Inhibitor Poisoning

* 2-PAM (Pralidoximine, 2-pyridine aldoxime methyl chloride)
* Organophosphate Poisoning IV: 30 mg/kg (Max 2g) then 8-10 mg/kg/hr (Max 650 mg/hr)
* Organophosphate Poisoning IM
  * Mild: 600mg IM repeat q15min PRN NTE 1800mg
  * Severe: 600mg IM rapid repeat NTE 1800mg
  * Persistent: May repeat 1800mg series q1h 
* Reversible Anticholinesterase Inhibitors: 2-PAM or Anticholinergic agents
  * 2-PAM: 1-2g IV then 250mg q5min PRN

# Anticholinergics

* Atropine
  * 0.5mg: Slight cardiac slowing, some oral dryness, and inhibition of sweating
  * 1mg: Tachycardia, mild mydriasis, oral dryness
  * 2mg: Tachycardia / palpitations, mydriasis, blurring of near vision, oral dryness
  * 5mg: All above SSx marked, difficulty speaking / swallowing, HA, hot / dry skin
  * &ge; 10mg: All above SSx, iris obliterated, vision very blurry, hallucinations, coma, ataxia
* Ipratroprium
  * COPD
* Scopolamine
  * Motion Sickness
  * Highest CNS penetration
* Homatropine
  * Cycloplegia and Mydriasis
* Tropicamide
  * Cycloplegia and Mydriasis
* Benztropine
  * PD and EPS
* Glycopyrrolate
  * GI Disorders (charged, won't enter CNS)
* Propantheline
  * GI Disorders (charged, won't enter CNS)

## Paralytics

**DO NOT ADMINISTER A PARALYTIC WITHOUT SUFFICIENT OPIOID ANALGESIA OR SIGNIFICANT SEDATION (Propofol, Ketamine, Etomidate, Volatile Anesthetics, etc)**

* Succinylcholine
  * 1-2 mg/kg IV or 4-5 mg/kg IM
  * Depolarizing blocker
  * Causes hyperkalemia
  * Short acting (effect ends in &approx;5 min)
* Non-Depolarizing
  * Vecuronium
    * 0.1 mg/kg
    * Lasts 30-60min
  * Pancuronium
    * 0.1 mg/kg
    * 45-90 min
  * Rocuronium
    * 0.8-1 mg/kg (30-45 min)